A Study to Test BI 655130 in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

    Not Recruiting
  • participants needed
  • sponsor
    Boehringer Ingelheim
Updated on 15 June 2021
Boehringer Ingelheim Call Center
Primary Contact
Nihon University Itabashi Hospital (2.3 mi away) Contact
+70 other location


To evaluate efficacy, safety, and tolerability of BI 655130 compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity

Condition Generalized Pustular Psoriasis
Treatment Placebo, BI 655130, Spesolimab
Clinical Study IdentifierNCT03782792
SponsorBoehringer Ingelheim
Last Modified on15 June 2021

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note